ArticleHeliyon2025

Efficacy of rituximab as second-line therapy for autoimmune encephalitis: A systematic review and meta-analysis.

Lin-Ming Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.